rMELEISH: A Novel Recombinant Multiepitope-Based Protein Applied to the Serodiagnosis of Both Canine and Human Visceral Leishmaniasis

Daniel Silva Dias, Juliana Martins Machado, Patrícia Aparecida Fernandes Ribeiro, Amanda Sanchez Machado, Fernanda Fonseca Ramos, Lais Moreira Nogueira, Ana Alice Maia Gonçalves, Luana de Sousa Ramos, Isadora Braga Gandra, Flaviane Silva Coutinho, Michelli dos Santos, Jonatas Oliveira da Silva, Miguel Angel Chávez-Fumagalli, Rafael Gonçalves Teixeira-Neto, Ana Thereza Chaves, Mariana Campos-da-Paz, Amanda A. Souza, Rodolfo Cordeiro Giunchetti, Sonia Maria Freitas, Sandra LyonDanielle Ferreira de Magalhães-Soares, Julia Angelica Gonçalves Silveira, Eduardo Sergio Silva, Eduardo Antonio Ferraz Coelho, Alexsandro Sobreira Galdino

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

2 Citas (Scopus)


Background: visceral leishmaniasis (VL) is a critical public health problem in over ninety countries. The control measures adopted in Brazil have been insufficient when it comes to preventing the spread of this overlooked disease. In this context, a precise diagnosis of VL in dogs and humans could help to reduce the number of cases of this disease. Distinct studies for the diagnosis of VL have used single recombinant proteins in serological assays; however, the results have been variable, mainly in relation to the sensitivity of the antigens. In this context, the development of multiepitope-based proteins could be relevant to solving such problem. Methods: a chimeric protein (rMELEISH) was constructed based on amino acid sequences from kinesin 39 (k39), alpha-tubulin, and heat-shock proteins HSP70 and HSP 83.1, and tested in enzyme-linked immunosorbent (ELISA) for the detection of L. infantum infection using canine (n = 140) and human (n = 145) sera samples. Results: in the trials, rMELEISH was able to discriminate between VL cases and cross-reactive diseases and healthy samples, with sensitivity and specificity values of 100%, as compared to the use of a soluble Leishmania antigenic extract (SLA). Conclusions: the preliminary data suggest that rMELEISH has the potential to be tested in future studies against a larger serological panel and in field conditions for the diagnosis of canine and human VL.

Idioma originalInglés
Número de artículo302
EstadoPublicada - feb. 2023


Profundice en los temas de investigación de 'rMELEISH: A Novel Recombinant Multiepitope-Based Protein Applied to the Serodiagnosis of Both Canine and Human Visceral Leishmaniasis'. En conjunto forman una huella única.

Citar esto